Interaction Guide · Research summary

Can I take Equisetum Arvense with Bumetanide?

Review Equisetum Arvense with Bumetanide: timing and monitoring, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

A required separation interval or universal avoidance rule for horsetail with bumetanide is not established. Review the product before adding it to prescribed diuretic treatment.

What this answer covers

Oral Equisetum arvense aerial-part products with bumetanide; defined extract evidence is short and healthy-population only.

Supplement or preparation
Equisetum arvense
Medication ingredient
bumetanide

The human trial did not test co-use

A four-day crossover study found a diuretic fluid-balance effect with a defined E.arvense aerial-part extract. It did not show significant urinary sodium or potassium change, and it did not test bumetanide. The findings cannot be treated as a demonstrated additive electrolyte-loss interaction.

People and products differed from this setting

The trial enrolled healthy men and excluded hypertension, heart disease and kidney disease. Many people prescribed bumetanide have conditions outside that population. Different horsetail species, teas, extracts and mixtures also cannot be assumed to match the studied product.

Review use before changing fluid management

Bumetanide requires individualized management because excessive diuresis can deplete fluid and electrolytes. Tell the treating team why you want to add horsetail and whether swelling or urine output has changed. Do not replace the prescription or rely on a few hours of spacing.

Report symptoms and changes

Report persistent dizziness, cramps, weakness, palpitations or a major change in swelling or urine output. Illness, dehydration and other medicines can contribute. Severe weakness, fainting or a new irregular heartbeat need prompt assessment. Do not treat symptoms by adding salts or increasing the diuretic yourself.

Evidence and practical considerations

Timing & monitoring

The available evidence does not establish a protective timing interval or universal avoidance requirement for E.arvense with bumetanide.

Exact scope
Oral Equisetum arvense aerial-part products with bumetanide; defined extract evidence is short and healthy-population only. with Exact bumetanide RxCUI1808 IN, confirmed by current RxNorm. Oral0.5/1/2mg tablets; no automatic IV equivalence or transfer of furosemide-ginseng report.
Medication form and route
Oral

What remains uncertain

  • No exact combination study or validated gap; short extract diuresis does not establish sodium/potassium wasting.

Factors that may matter: Exact preparation and dose; Kidney function; Baseline electrolyte status; Other medicines.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: Current prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Patients prescribed oral bumetanide tablets.

Potassium loss is dose-related; periodic potassium checks and replacement if necessary. Class magnesium-loss warning and other electrolyte checks in prolonged/high-dose use. Excess diuresis causes fluid/electrolyte depletion.

How this applies: Exact medication label. Exact bumetanide RxCUI1808 IN, confirmed by current RxNorm. Oral0.5/1/2mg tablets; no automatic IV equivalence or transfer of furosemide-ginseng report.

Class magnesium warning is not universal deficiency; healthy low-dose trial and PPI-associated case limitations retained.

Source 2: Original clinical research

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: 36 healthy men; heart, kidney disease and hypertension excluded.

Diuretic fluid-balance effect without significant urinary sodium or potassium change; safety laboratory values remained normal.

How this applies: Applicability is limited to the stated exact medication, preparation and endpoint; other-drug evidence is indirect.

Short healthy trial, no digoxin or bumetanide co-use. HCTZ comparator does not make the herb a sodium/potassium-wasting equivalent.

Source 3: Medication terminology

rxnav.nlm.nih.gov · Source check Sep 10, 2026

Population: Terminology.

bumetanide is IN.

How this applies: Exact ingredient.

Not clinical evidence.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Sources checked and article drafted.
Research summary published

Article revision: f0598c187d444246

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.